fintols

Grifols vs Laboratorios Rovi (GRF vs ROVI)

Grifols (GRF) vs Laboratorios Rovi (ROVI) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.

Grifols (GRF) and Laboratorios Rovi (ROVI) compete in healthcare and pharma. Here are Grifols and Laboratorios Rovi side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Grifols or Laboratorios Rovi.

Grifols vs Laboratorios Rovi: the figures

FigureGrifolsLaboratorios Rovi
Share price€11.22 (November 4, 2026)€63.75 (November 4, 2026)
Market cap€7.6 billion€3.3 billion
P/E (TTM)15.8x17.6x
Forward P/E10.1x19.4x
Revenue growth (quarter)+9.4%+20.0%
Net margin (TTM)6.4%24.0%
Net debt / EBITDA5.0xNet cash
Dividend yield0.73%1.52%
BetaN/A0.29

Grifols and Laboratorios Rovi figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Grifols or Laboratorios Rovi figure is not available, and we never estimate it.

3 key differences between Grifols and Laboratorios Rovi

  1. Debt: Grifols owes 5.0x its annual operating profit (EBITDA), while Laboratorios Rovi holds more cash than debt.
  2. Profitability: for every 100 of sales, Laboratorios Rovi keeps 24.0 as net profit and Grifols keeps 6.4.
  3. Growth: Laboratorios Rovi grew sales +20.0% year on year in its latest quarter, against +9.4% for Grifols.

Grifols or Laboratorios Rovi: which fits your profile

Neither Grifols nor Laboratorios Rovi wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

How Grifols and Laboratorios Rovi make money

Grifols (GRF)

Grifols collects plasma from donors at its network of centers, mostly in the US, and turns it into medicines. Its Biopharma division, the largest, sells immunoglobulins, albumin and other plasma proteins to hospitals; Diagnostic provides blood-screening tests for blood banks and labs; and Bio Supplies sells biological materials. Full Grifols analysis.

Laboratorios Rovi (ROVI)

Rovi has two businesses. Specialty pharmaceuticals, its biggest, sells heparins such as biosimilar enoxaparin and bemiparin, plus drugs like the schizophrenia treatment Okedi. Its contract manufacturing arm produces injectable drugs and vaccines for other drugmakers, including Moderna. Spain is its largest market. Full Laboratorios Rovi analysis.

Frequently asked questions: Grifols vs Laboratorios Rovi

Is Grifols or Laboratorios Rovi the better stock?

Choosing between Grifols and Laboratorios Rovi depends on what you are looking for. Laboratorios Rovi is growing faster right now, and Grifols trades on the lower P/E. Fintols does not tell you whether to buy Grifols or Laboratorios Rovi: it shows you the differences so you can decide.

Which pays a higher dividend, Grifols or Laboratorios Rovi?

As of November 4, 2026, Laboratorios Rovi yields 1.52% and Grifols yields 0.73%. Also check how much of their profit Grifols and Laboratorios Rovi pay out: if it is more than they earn, it cannot last.

Which is more expensive, Grifols or Laboratorios Rovi?

On P/E, Laboratorios Rovi (17.6x) is more expensive than Grifols (15.8x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.

Can I own both Grifols and Laboratorios Rovi?

Yes. Many people spread their money across several companies, such as Grifols and Laboratorios Rovi, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Grifols or Laboratorios Rovi.

More comparisons with Grifols or Laboratorios Rovi

More companies like Grifols and Laboratorios Rovi: healthcare and pharma stocks. Educational content about Grifols and Laboratorios Rovi, not investment advice.